Compare LOOP & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOOP | ACET |
|---|---|---|
| Founded | 2010 | 1947 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.8M | 69.6M |
| IPO Year | 2010 | 2017 |
| Metric | LOOP | ACET |
|---|---|---|
| Price | $1.30 | $7.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $65.33 |
| AVG Volume (30 Days) | 45.0K | ★ 173.0K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.27 | ★ 59.82 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,889,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $174.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7016.99 | N/A |
| 52 Week Low | $0.88 | $0.45 |
| 52 Week High | $2.29 | $9.05 |
| Indicator | LOOP | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 57.53 | 52.19 |
| Support Level | $1.17 | $0.64 |
| Resistance Level | $1.35 | $8.46 |
| Average True Range (ATR) | 0.06 | 0.46 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 64.71 | 70.22 |
Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.